ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026

ArriVent BioPharma, Inc.

• Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).
• Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.
• Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.
• FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.
• ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.